Biologics

India’s biotechnology sector buzzes with potential, yet a frustrating disconnect persists between government promises and ground realities. Whilst the Department of Biotechnology launches ambitious schemes worth thousands of crores, startup founders in Bengaluru and Hyderabad tell different stories. They speak of delayed funding, bureaucratic labyrinths, and support that sounds impressive on paper but rarely materialises

There’s a particular irony in modern medicine: the most sophisticated treatments often look deceptively simple. A clear vial containing colourless liquid might cost thousands of pounds per dose, yet inside swim precisely engineered proteins capable of seeking out and destroying cancer cells whilst leaving healthy tissue untouched. These are monoclonal antibodies—amongst the most revolutionary therapeutics

India’s pharmaceutical sector stands at a paradoxical crossroads where technological capability dramatically outpaces clinical execution, creating both extraordinary opportunity and persistent frustration. The nation is rapidly emerging as a significant global player in drug discovery, driven by its highly skilled scientific workforce, substantial cost advantages, and growing investments from domestic and international sources seeking alternatives

India’s biologics market is experiencing a transformation that’s catching global pharmaceutical giants off guard and reshaping competitive dynamics in biotechnology. Led by the explosive rise of bioconjugates and biosimilars as major growth drivers, India is rapidly evolving from a generic drugs manufacturer into a sophisticated biotech innovator capable of producing some of the world’s most

America’s insulin crisis just met its match. Biocon Biologics is mounting an aggressive expansion into the United States diabetes market, targeting millions of Americans struggling with soaring insulin costs. The fully integrated global biosimilars company, a subsidiary of Biocon Ltd., aims to provide high-quality, affordable insulin alternatives to approximately 38.4 million Americans living with diabetes—roughly

The biopharmaceutical industry’s most explosive growth story isn’t happening inside pharmaceutical giants’ research labs. It’s unfolding within specialized contract manufacturing organizations producing tomorrow’s life-saving therapies. The biologics contract manufacturing market will more than double from approximately $35.9 billion in 2025 to roughly $71.8 billion by 2032, reflecting compound annual growth exceeding 10%. This isn’t incremental